Teclistamab (Tecvayli)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses teclistamab (Tecvayli), 10 mg/mL or 90 mg/mL single-dose vials containing 30 mg teclistamab in 3 mL solution or 153 mg teclistamab in 1.7 mL solution, subcutaneous injection.
• Indication: Teclistamab injection is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.